Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets. 2022

Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
Torii Pharmaceutical Co. Ltd., Tokyo, Japan.

Sublingual allergy immunotherapy tablets (SLIT-tablets) provide a well-tolerated and clinically efficacious treatment for allergic disease such as allergic rhinitis and allergic asthma. In SLIT, uptake of allergen by immune-competent cells in the oral mucosa activates the immune system and leads to tolerance toward the sensitizing allergen. The ability to deliver the full allergen content into solution within the recommended sublingual holding time is therefore an essential quality of SLIT-tablets that must be supported by the tablet formulation for all relevant allergen sources. SLIT-tablets based on a fast-dissolving orodispersible freeze-dried formulation (Zydis) are currently available for 5 of the most prevalent allergens: tree (birch and related species from the birch-homologous group), grass, ragweed, Japanese cedar, and house dust mite. The purpose of this study was to examine the allergen release properties of three freeze-dried SLIT-tablets containing tree, ragweed, and Japanese cedar extracts, respectively. The correlation between SLIT-tablet allergen release and the level of allergen-specific T-cell activation was examined for the tree SLIT-tablet. Allergen release kinetics and tablet disintegration times for the 3 freeze-dried SLIT-tablets were examined. For all 3 tablets, the magnitude of solubilized major allergen relative to time in solution was compared to external controls to achieve a measure of the total allergen release. Additional assessments of allergen release occurring after the initial timepoint (15 or 30 seconds in solution) were done independently of external controls by linear regression analyses. For the tree SLIT-tablet, the immunological potency of the released major allergen was assessed at each experimental timepoint by a Bet v-specific T-cell activation assay. All 3 SLIT-tablets disintegrated within 1 second after contact with assay buffer without any detectible residue. Complete release of major allergens (Bet v 1, Amb a 1, and Cry j 1, respectively) was seen at the earliest experimental time points (15 or 30 seconds). For the tree SLIT-tablet, full T-cell activation was achieved at 30 seconds (earliest experimental time point). The freeze-dried SLIT-tablet formulation consistently provides rapid and complete release of allergen from a wide range of species in a standardized in vitro assay. Full release of the SLIT-tablet allergen content within the sublingual holding time is a prerequisite for maximal exposure of allergens to the sublingual mucosa immune system. The freeze-dried SLIT-tablet formulation examined here supports short sublingual holding times and furthermore offers a convenient administration form of allergy immunotherapy.

UI MeSH Term Description Entries

Related Publications

Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
April 2024, Pharmaceutical development and technology,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
April 2019, Clinical therapeutics,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
June 2018, Pharmaceutical development and technology,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
December 2016, Drug development and industrial pharmacy,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
January 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
January 2018, Drugs in context,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
June 2019, eNeurologicalSci,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
November 2013, Journal of clinical pharmacology,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
January 2020, International journal of pharmaceutical compounding,
Takashi Yamamoto, and Katsuyo Ohashi-Doi, and Hiroki Matsuhara, and Loes Verhoog, and Morten Lindholm, and Simon Lawton, and Kaare Lund
January 2021, Allergy and asthma proceedings,
Copied contents to your clipboard!